Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Poison pills are just a tool and that's all. It does not guarantee anything and not too much should be made of the whole concept IMO.
I'd like to ask the cousins to stop selling please.
I don't know about that Cromangon, you are making quite a few assumptions vis. the data, "cousins?" This trial is no magnet for evildoers IMO.
Seems like a lot of HIV drug candidate failures.
Dec 12, 2007 (Datamonitor via COMTEX) -- Trimeris has suffered from a low
uptake of its HIV product Fuzeon, partly because the salvage therapy market is
shrinking and becoming more crowded due to the launch of new drug classes. This
will also affect other companies developing products for this market, including
Panacos Pharmaceuticals.
US-based Trimeris announced that it will halt its HIV and AIDS R&D activities
and lay off staff in 2008. Trimeris, together with Swiss company Roche, launched
HIV drug Fuzeon (enfuvirtide) in 2003 in the US and EU. Being the first entry
inhibitor available on the market, it was a welcome addition to the
antiretroviral drug portfolio, particularly for patients who had limited
therapeutic options. However, its cost and twice-daily subcutaneous
administration has restricted its uptake.
Although the drug has dominated the salvage therapy market for some time, Fuzeon
faces a significant threat from other new classes like CCR5 inhibitors and
integrase inhibitors that are delivered orally and target the same group of
treatment-experienced patients. On top of this, the salvage market will overall
experience a decrease in patient numbers due to improved efficacy and
convenience of first-line treatment, leaving patients on their initial therapies
for longer.
Trimeris and Roche both withdrew an application to sell a needle-free device for
injecting Fuzeon after federal regulators asked for more data in October 2007.
Furthermore, in March of the same year, Roche returned the rights to joint
patents and intellectual property related to next-generation HIV fusion
inhibitor peptides, including TRI-1144, an experimental drug Trimeris and Roche
were developing under a 2000 agreement.
Another company that will be struggling to enter the HIV salvage market is
Panacos, a US-based biotechnology company. Its first-in-class maturation
inhibitor bevirimat (PA-457) is also in development for patients failing HIV
therapy due to drug resistance. However, data presented this week suggested that
this drug is only effective in an unknown subpopulation, demonstrating the need
for extra clinical trials. Additionally, after having failed to develop this
drug as tablets, a liquid formulation is now being pursued which may further
hamper entry into the competitive tablet-dominated salvage market.
Trimeris's downfall illustrates the rising demands on convenience and efficacy
for both new and existing HIV drugs. As for Panacos, the formulation issues
coupled with new doubts over bevirimat's efficacy illustrates the big challenge
the company is facing.
PANC worth considering? TIA
LOL, that's funny.
Regarding percentages, how the heck am I ever supposed to get that fabled 5X - 10X gain on an investment if I adhere to the 10% max rule? Conversely, if GTCB is now 10% of my investment portfolio, what was it when the stock traded at $1.20?
I just continue to do what makes sense to me from a risk point of view. If that means a stock gets to be greater than 10% for awhile, so be it. It doesn't mean much. There is probably a Will Rogers quip that fits here.
Cro, if your average share price is $1.04, then you should be sleeping soundly at night. Averaging into a position like this can take you down easily more than a 20% loss before healing (if it ever comes). You are in good shape man! Count your blessings. If you start trading this, you could end up trading it all away. Beware the trade.
Way OT:
What should be one's response to H2O2 therapy?
A) Forget about it
B) Research it and possibly use it for variety of ailments
C) "Good for what ails ya"
TIA, Thanks
Thanks, definitely material.
How much is a FDA user aplication fee?
Pretty clear recap, thanks.
Lake, you have to "know what you are holding". That helps to weather the storms. If GTC is worth anything at all, it is worth .90! So, don't worry about .70.
>>despite the small HD rev indication<<
Not to pick on terminology, but small is a relative term. For GTC, not "small" as I learned awhile back. Well worth doing. Meaningful revenue, in addition to being a prelude for Atryn in DIC.
Well, to your point, I called the CFO of COLY a few weeks ago after I had bought some shares and wanted to buy more. He was rather short with me when it came to the questions I was asking and basically told me that biotech investing was very complex and that is why institutions have experts and people like me (I inferred this) should stay away.
Well, as it turned out, I was perfectly able to discern value in the market and the rest is history.
Bottom line, you listen, you weigh it out, you decide, you don't point a finger, especially at yourself.
Bought today at .9101
I don't recall Dew ever saying "buy" or "sell". He has said that GTC is one of his major investments and obviously he believes strongly in the company. I have nothing but thanks to offer for the unselfish flow of solid factual information and ready, clear and concise answers to every question I have ever posed. Thanks again, and a very merry Christmas to you Dew. I don't mean to slight others here who provide solid analysis too.
In general, how does this election cycle affect pharma stocks? If pols were to indicate a landslide for Dems vs. a landslide for Reps, how would the sector respond? Is the prospect of nationalized health care a reason that some of these biotechs are depressed?
Mary Ann Gray seems a great addition to the board. I think GTC needs her.
http://biz.yahoo.com/bw/071206/20071206005551.html?.v=1
As near as I can tell, the milk patents don't have teeth, they just suck :)
This reminds me of the lady who went to the acadamy to see her son march with the corps. She said, "Everyone is out of step but my Johny!" I feel like Johny, buying when everyone else is selling. It is what it is.
Price is dropping faster than JP can spend money.
Well, I saw a closing price at 16:05 or 99.98 and I see a close on Scottrade of $1. Hope this qualifies as a $1 close.
Mostly buying today. Would be nice to close above a buck for listing requirements. I don't think intraday prices count.
Now, why would anyone want to block a $1 close?
Other than the fact that it is dropping like a damn rock, no. IDIX needs to get it's poop in a group IMO.
How the heck do you interpret the charts? I mean, there is the obvious answer, and then there is an answer based on your modus operandi of buying cash rich biotech.....
Weakness today. Started a position. Any deviations from Yahoo! key statistics that I should be aware of? Or other glaring "issues" that I should be aware of? Thanks.
Sold $1.86. BTW, thanks for the comments on NUVO. I had been watching for a long time and finaly decided that I would follow your lead here. Lucked out I guess @ $1.35. Still holding GLGC and IDIX and GTCB. Do you have any others below cash?
Well, the "free" ones didn't last long today.
Free ownership of Tyzeka/Sebivo today! Read all about it. Stock market values the worldwide drug at zero and is giving it away while supplies last. Tomorrow you may get it for even less than zero. Read all about it.
Seems IDIX's restructuring to a percentage of worldwide sales may have been a smart move, considering the slow uptake in the US.
Thanks for coming around somewhat. Good luck to you.
LOL, cato, for the sake of others who may be reading this board and not to argue with you personally, but I discussed this very issue with the CFO at some length and I discovered that it does indeed require significant commitment and money for a partner to do repositioning. In some cases, the partner actually shares expenses as they occur and each case, I guess is unique to some degree. Believe what you want, you seem to want to believe the worst about GLGC - what is your motive?
Cato, I believe you are wrong but I won't argue about it any more. My belief comes from DD I did awhile back because that was an obvious question which I addressed. Good luck.
100% probability - that's pretty high. I think GTC is going to avoid major dillution. I think they do that the way they have been for the past 6 months, that is following through in actions what they stated in that Q2 CC. I have been encouraged by the reduction in cash burn. I think they realize they cannot go to the market with more shares at these prices. I could be wrong.
Atryn revenue could begin to make a difference in 2008. No revenue is irrelevant.
Resisting the urge to swear.....thoughts turning to the wild grape.....stop trying to make sense of this......drug stocks not kind to me......listen to some music.......
If a major drug company does trials, perhaps all the way through PIII, then transfers the entire data set to GLGC for additional analysis, I call that a significant commitment and requires significant trust and, BTW I know for a fact that it cost them significant money.
No, this characterization is certainly incorrect. It does cost these companies money, time, energy, etc. How do you think all the prior discovery gets over to GLGC? Why would they trust just anyone with this information, some even may be inside info and proprietary? It would be stupid for any major drug company to allow GLGC to "dig around in my backyard" unless they had some level of hope and trust.
Yes, there have been results from the genomics division. Exactly how might you differentiate between what was sold and what was retained? I maintain that results are just as probable now as then, I mean, there are 8 larger and well financed companies that currently trust GLGC to do work for them in this capacity. Results could be today, tomorrow, next year or never. That is the reward/risk profile here. However, today we are talking major discount to cash, book value, and quite low cash burn into the next quarters (with the exception of this current quarter which is up for speculation.
It was producing revenue - declining revenue - but, yes, I think many shareholders decided that a non-revenue producing drug company = sell.
But this has to be a buy with what I believe will be close to $1.30 or more at year end. There is a 1.5M payment due from prior sale of division I believe near year end. Also, I think we have some tangible assets in terms of property, plant and equipment. Blah, blah, ...... price keeps going down for about 12 days now. Oh yeah, there are those short shares...
Just one of perhaps many cases. This is unique in that this company decided to reveal that GLGC's genomics division did the discovery.
Need to remember that GLGC still has virtually all of the capabilities regarding discovery that it has had and has decided that the best way to use that data is through repositioning; and it makes sense to let the larger companies come up with the initial discovery and testing, even trials, and then let GLGC try to find potential in them.
I voted no on name change.